Development of a non-invasive CLDN18.2 methylation biomarker

Development of a non-invasive CLDN18.2 methylation biomarker associated with the therapeutic effect of zolbetuximab - Development of a non-invasive CLDN18.2 methylation biomarker associated with the therapeutic effect of zolbetuximab

Status

Recruiting

Phases

Phase 4

Study type

Observational

Source

JPRN

Registry ID

JPRN-jRCT1031250588

Enrollment

500

Registered

2025-12-22

Start date

2025-07-14

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastric Cancer gastric cancer

Interventions

none

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients who meet all of the following criteria are eligible: 1. Patients diagnosed with gastric cancer and treated at Yamanashi University Hospital between 2015 and 2027 2. Patients aged 18 years or older

Exclusion criteria

Exclusion criteria: Patients who fall into any of the following categories will be excluded from the study: 1. Patients with multiple cancers 2. Patients who are otherwise deemed inappropriate by a physician

Design outcomes

Primary

Measure	Time frame
Correlation between CLDN18.2 expression and CLDN18.2 DNA methylation status in gastric cancer tissues	—

Secondary

Measure	Time frame
Correlation with treatment effect	—

Contacts

Public ContactKatsutoshi Shoda

First Department of Surgery, Faculty of Medicine University of Yamanashi

kshoda@yamanashi.ac.jp+81-55-273-7390

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026